16th Feb 2023 13:29
(Alliance News) - Arecor Therapeutics PLC on Thursday celebrated several patent wins in the US and India, as it looks to strengthen its portfolio of pharmaceutical products.
Arecor is a Cambridgeshire, England-based biopharmaceutical company focused on bringing new medicines to market through the enhancement of existing therapeutic products.
The firm said that the Indian Patent Office has granted a patent protecting novel formulations of the its proprietary insulin products, AT247 and AT278, until 2038. The products have been designed to significantly accelerate insulin absorption post injection across a range of insulin concentrations, enabling more effective management of blood glucose levels for people living with diabetes.
In addition, the US Patent and Trademark Office has granted two patents protecting the group's novel formulations of high-concentration adalimumab until 2038. Sold by AbbVie under the brand name Humira, adalimumab is a monoclonal antibody product.
"As we continue to successfully apply our Arestat technology to develop enhanced pharmaceutical products, it is crucial that we maintain strong IP protection, both for the fundamental features of our technology and for the final drug products," said Chief Scientific Officer Jan Jezek.
"These three recently granted patents demonstrate the continued strength of Arecor's IP portfolio, providing further protection for our differentiated in-house development products AT247 and AT278, as well as within competitive IP areas such as that surrounding adalimumab formulations. These patents further reinforce the strength of Arecor's technology and expertise in valuable commercial areas such as inflammatory diseases and diabetes."
Arecor shares were flat at 240.00 pence each in London on Thursday afternoon.
By Holly Beveridge; Alliance News reporter
Comments and questions to [email protected]
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Related Shares:
Arecor Therape